Content contributed by the Alzheimers Association A glucagon-like peptide-1 (GLP-1) drug appears to slow cognitive decline by protecting the brain, according to Phase 2b clinical trial data reported recently at the Alzheimers Association International Conference (AAIC) 2024, in Philadelphia and online
Hypersensitivity may develop in patients previously given thiamine, specially after repeated injections of concentrated solution
Currently, there are three FDA-approved semaglutide products: Ozempic, Wegovy, and Rybelsus
Semaglutide can treat: Excess fat in the stomach, thighs, buttocks, arms, and more High blood sugar Poor cardiac health Obesity When paired with lifestyle adjustments, such as a healthier diet and increased activity, semaglutide has transformational effects